A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants
A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants
The purpose of this study is to evaluate the bioavailability of teduglutide administered as a
 single subcutaneous (SC) fixed dose (depending upon participant weightband assignment)
 delivered by a syringe injection and the same fixed dose delivered by the pen injector in
 healthy participants.
This is a 2-period crossover study and consists of two cohorts. Cohort 1 consists of
 participant's with greater than or equal to (>=) 40.0 kilogram (kg) to lesser than or equal
 to (<=) 75.0 kg of weight and Cohort 2 consists of participant's with greater than (>) 75.0
 kg to <= 120.0 kg of weight. Participants in each cohort will be randomized to 1 of 2
 treatment periods (Period I and Period II) with sequence AB and BA. Randomization will be
 stratified by injection site (i.e., thigh, abdomen, and arm) within each cohort.
Inclusion Criteria:

 -  An understanding, ability, and willingness to fully comply with study procedures and
 restrictions.

 -  Ability to voluntarily provide written, signed, and dated informed consent and assent
 as applicable to participate in the study.

 -  Aged 18 - 45 inclusive at the time of consent. The date of signature of the informed
 consent is defined as the beginning of the screening period. This inclusion criterion
 will only be assessed at the first screening visit.

 -  Male, or non-pregnant, non-lactating female who agrees to comply with any applicable
 contraceptive requirements of the protocol or females of non-childbearing potential.

 -  Considered "healthy" by the investigator. Healthy status is defined by absence of
 evidence of any active or chronic disease following a detailed medical and surgical
 history, a full physical examination including vital signs, 12-lead electrocardiogram
 (ECG), hematology, coagulation (as appropriate), serum chemistry, and urinalysis.

 -  Body mass index (BMI) >= 18.0 and l<=32.0 kilogram per square meter (kg/m^2) at
 screening. Body weight for a participant in Cohort 1 will be >= 40.0 kg to <= 75.0 kg,
 and body weight for a participant in Cohort 2 will be > 75.0 kg to <= 120.0 kg,
 inclusive. This inclusion criterion will be assessed at the screening visit and
 confirmed at first check-in.

 Exclusion Criteria:

 -  History of any hematological, hepatic, respiratory, cardiovascular, renal,
 neurological or psychiatric disease, gall bladder removal, or current or recurrent
 disease that could affect the action, absorption, or disposition of the
 investigational product, or clinical or laboratory assessments.

 -  Current or relevant history of physical or psychiatric illness, any medical disorder
 that may require treatment or make the participant unlikely to fully complete the
 study, or any condition that presents undue risk from the investigational product or
 procedures.

 -  Positive PCR (polymerase chain reaction) test for severe acute respiratory syndrome
 coronavirus-2 (SARS-CoV-2), either with the absence or presence of the clinical
 symptoms of Coronavirus disease 2019 (COVID-19).

 -  Known or suspected intolerance or hypersensitivity to teduglutide, closely-related
 compounds, or any of the stated ingredients.

 -  Significant illness, as judged by the investigator, within 2 weeks of the first dose
 of teduglutide.

 -  Known history of alcohol or other substance abuse within the last year prior to
 screening.

 -  Donation of blood or blood products (e.g. plasma or platelets) within 60 days prior to
 receiving the first dose of teduglutide.

 -  Pregnant or lactating female.

 -  Within 30 days prior to the first dose of teduglutide:

 1. Have used an investigational product (if elimination half-life is lesser than [<]
 6 days, otherwise 5 half-lives)

 2. Have been enrolled in a clinical study (including vaccine studies) that, in the
 investigator's (or designee's) opinion, may impact this study

 3. Have had any substantial changes in eating habits, as assessed by the
 investigator (or designee)

 -  Use of dipeptidyl peptidase 4 inhibitors within 30 days or 5 half-lives, whichever is
 greater, prior to administration of the first dose of teduglutide.

 -  Confirmed systolic blood pressure > 140 millimeter of mercury (mmHg) or < 90 mmHg, and
 diastolic blood pressure > 90 mmHg or < 40 mmHg at screening.

 -  Twelve-lead electrocardiogram (ECG) demonstrating QTcF > 450 milliseconds (msec) at
 screening. If the QTcF exceeds the aforementioned limits, the ECG should be repeated 2
 more times and the average of the 3 QTcF values should be used to determine the
 participants eligibility.

 -  Positive screen for drugs of abuse or alcohol at screening and at each check-in.

 -  Male participants who consume more than 21 units of alcohol per week or regularly
 consume more than 3 units per day. Female participants who consume more than 14 units
 of alcohol per week or regularly consume more than 2 units per day. (1 alcohol
 unit=150 milliliter [mL] of wine, or 360 mL of beer, or 45 mL of 45 percent [%]
 alcohol).

 -  Positive Human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or
 Hepatitis C virus (HCV) antibody screen at screening.

 -  Use of tobacco in any form (e.g. smoking or chewing) or other nicotine-containing
 products in any form (e.g. gum, patch) based on participant self-reporting. Ex-users
 must report that they have stopped using tobacco for at least 3 months prior to
 receiving the first dose of teduglutide.

 -  Routine consumption of more than 2 units of caffeine per day or participants who
 experience caffeine withdrawal headaches. One caffeine unit is contained in the
 following items: one 6 ounce (oz) (180 mL) cup of coffee, two 12 oz (360 mL) cans of
 cola, one 12 oz (360 mL) cup of tea, three 1 oz (85 gram [g]) chocolate bars.

 -  Prior screen failure, randomization, participation, or enrollment in this study, or
 prior exposure to any Glucagon-like peptide 2 (GLP-2) analogs.

 -  Presence of lesions, rashes, tattoos, and moles etc. on administration sites not
 allowing adequate conduct of injection site reaction and injection site injury
 assessment

 -  Current use of any medication (including over-the-counter, herbal, or homeopathic
 preparations; with the exception of occasional use of ibuprofen [1.2 g per 24 hour
 period] or acetaminophen [2 g per 24 hour period]). Current use is defined as use
 within 14 days of the first dose of teduglutide and throughout the study.